Medical journal publishes Vioxx correction
New England journal posting on study could undermine Merck defense.
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- The New England Journal of Medicine posted a correction in its current issue, removing its previously published finding that it takes at least 18 months for heart attack risks to increase from use of Vioxx, the anti-arthritis painkiller that Merck pulled from the market.

The correction could be used as a legal weapon against Merck (up $0.34 to $35.28, Charts), the drugmaker that withdrew Vioxx, a former blockbuster, in 2004 as a result of this "Approve" study. Since then, more than 10,000 lawsuits have been filed against the drugmaker from former Vioxx patients and their families, blaming the drug for causing heart attacks.

merck_vioxx.03.jpg

The original finding, that risks emerged only after 18 months of Vioxx use, has been used by Merck's lawyers as an important part of its defense. The NEJM finding could undermine that strategy.

The NEJM correction stems from an announcement that Merck made May 30. Merck said it was correcting its "prior description of one of the statistical methods used in the Approve study."

On Monday, Merck stood by its original results for the Approve study, acknowledging a heightened risk of heart attacks after 18 months of Vioxx use, but not before.

"As we have said previously and affirm today, this correction did not change the data in the Approve study or its results," said Peter Kim, president of Merck Research Laboratories, in a press release.

Merck was preparing to respond to the publication of the correction.

Related: Best spinner could be the winner Top of page

YOUR E-MAIL ALERTS
Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.